Nav: Home

Ross River virus battle breakthrough

September 07, 2016

Research conducted by Griffith University and Melbourne-based company Paradigm Biopharmaceuticals Limited (ASX: PAR) has uncovered a potential new therapeutic treatment for the global battle against mosquito-borne alphavirus infections, including the debilitating Ross River Virus (RRV) and Chikungunya Virus (CHIKV).

Currently RRV and CHIKV sufferers are only offered symptomatic management in the form of either non-steroidal anti-inflammatories or corticosteroids, which in some cases may actually exacerbate the condition.

These therapeutics may offer some short-term symptomatic relief but their use often results in detrimental side-effects while failing to treat the underlying disease.

Researchers at Griffith University may have discovered a breakthrough in the treatment of mosquito transmitted viral diseases like RRV and CHIKV.

Pre-clinical experiments conducted by researchers at Griffith University's Institute for Glycomics on the Gold Coast have demonstrated world-first results showing that the historic drug, pentosan polysulfate sodium (PPS), can successfully treat both the acute and chronic disease manifestations symptoms of alphavirus infections in the animal model.

Several human patients have also been treated with PPS under the Therapeutic Goods Administration Special Access Scheme. These patients, who previously were severely debilitated and had difficulty with daily activities, have reported remarkable improvements in their physical capabilities and general well-being. In these RRV patients treated with PPS the results demonstrate the drug was well tolerated and produced strong signals of clinical effects.

Queensland man Jon Chaseling said, "I suffered the effects of Ross River Fever for years. Most days I found it nearly impossible to do something as simple as walking down a flight of stairs. I avoided shaking hands with people because of the pain it caused. Even the weight of the bedclothes at night was agonising. Since undergoing a course of treatment with PPS, I find I'm far more mobile and in much less pain. It's literally changed my life."

Lead researcher, Dr Lara Herrero, became interested in alphaviruses after becoming infected with Ross River virus in Western Australia in 2004.

"Alphavirus infection is characterised by crippling musculoskeletal pain, inflammation and swelling in the joints, often leading to the destruction of cartilage," she said. "Currently there's only symptomatic relief available to RRV and CHIKV sufferers with the use of either non-steroidal anti-inflammatories or corticosteroids, both which can have detrimental side-effects and in some cases may actually exacerbate the condition. But when PPS was used to treat the viral disease in the mouse model, we observed a significant reduction in musculoskeletal damage. These data point to PPS being a well-tolerated anti-inflammatory therapy and also a disease modifying drug by protecting the joint cartilage".

"We're extremely encouraged by the preclinical results and five clinical cases but our next step is to confirm these results in a Phase 2 clinical trial" said Mr Paul Rennie, CEO of Paradigm Biopharmaceuticals.

Griffith University and Paradigm Biopharmaceuticals have entered into a commercialisation agreement under which Paradigm will fund and undertake the necessary clinical trials. If the trials are successful Griffith University will receive a royalty on Paradigm's sale of the drug to treat viral arthritis.
-end-
About Ross River Virus and Chikungunya Virus

Ross River virus is a mosquito-transmitted alphavirus that causes epidemic polyarthritis and bone pain. It is Australia's most common arbovirus with about five thousand cases notified each year. [Ref: Australian Family Physician Vol 36 No. 8 Aug 2009]

Chikungunya virus, also a mosquito transmitted alphavirus, originated in Africa and has since expanded its global range with outbreaks occurring in several other continents. In 2006-2007 a large outbreak of chikungunya occurred in India with several other countries in South-East Asia also affected. Since 2005, India, Indonesia, Maldives, Myanmar and Thailand have reported over 1.9 million cases. In 2007 transmission was reported for the first time in Europe with the first case originating from a returned traveller. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean also in South America - areas in which chikungunya was not previously transmitted. Local transmission has also occurred in the United States, where the virus was previously unknown. Experts predict is just a matter of time before local transmission occurs in Australia. There is a risk that the virus will be imported to new areas by infected travellers. As noted previously, there is no vaccine to prevent or drugs to treat Ross River or chikungunya virus infections. [Ref: WHO website, CDC website and Time.com]

About the Institute for Glycomics

The Institute for Glycomics is a flagship biomedical research institute at Griffith University's Gold Coast Campus. Since its inception in 2000, the Institute for Glycomics quickly became recognised as one of the largest in the world with a core focus on this complex and emerging field of research. It was the glycomics approach that led to the discovery of the world's first drug against the influenza virus, Relenza®, and the award of the Australia Prize to the Director of the Institute for Glycomics, Professor Mark von Itzstein.

Today, the Institute has some of Australia's most renowned research leaders and state-of-the-art facilities. The unique, multidisciplinary approach and extraordinary research capacity is now being used to develop the next generation of drugs and vaccines to fight diseases of global impact.

About Paradigm Biopharmaceuticals Ltd:

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is an Australian biopharmaceutical company focused on repurposing the historic drug PPS (Pentosan Polysulfate Sodium) as a potential new treatment for Bone Marrow Edema (BME) lesions following traumatic injury. Paradigm Biopharmaceuticals is also repurposing PPS for respiratory diseases including Allergic Rhinitis (AR) also known as hay fever. Repurposing an existing drug diminishes early developmental risks associated with traditional new drug development and usually means shorter development times, lower development costs and less safety risk.

ABN: 94 169 346 963
http://paradigmbiopharma.com

Griffith University

Related Pain Articles:

It's not just a pain in the head -- facial pain can be a symptom of headaches too
A new study finds that up to 10% of people with headaches also have facial pain.
New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.
The insular cortex processes pain and drives learning from pain
Neuroscientists at EPFL have discovered an area of the brain, the insular cortex, that processes painful experiences and thereby drives learning from aversive events.
Pain, pain go away: new tools improve students' experience of school-based vaccines
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) have teamed up with educators, public health practitioners and grade seven students in Ontario to develop and implement a new approach to delivering school-based vaccines that improves student experience.
Pain sensitization increases risk of persistent knee pain
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis (OA), according to a new study by researchers from the Université de Montréal (UdeM) School of Rehabilitation and Hôpital Maisonneuve Rosemont Research Centre (CRHMR) in collaboration with researchers at Boston University School of Medicine (BUSM).
Becoming more sensitive to pain increases the risk of knee pain not going away
A new study by researchers in Montreal and Boston looks at the role that pain plays in osteoarthritis, a disease that affects over 300 million adults worldwide.
Pain disruption therapy treats source of chronic back pain
People with treatment-resistant back pain may get significant and lasting relief with dorsal root ganglion (DRG) stimulation therapy, an innovative treatment that short-circuits pain, suggests a study presented at the ANESTHESIOLOGY® 2018 annual meeting.
Sugar pills relieve pain for chronic pain patients
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology.
Peripheral nerve block provides some with long-lasting pain relief for severe facial pain
A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia (TGN) may produce long-term pain relief.
How do you assess pain in children who can't express themselves? New research identifies priorities in identifying pain in nonverbal children with medical complexity
Pain is a frequent problem for children with complex medical conditions -- but many of them are unable to communicate their pain verbally.
More Pain News and Pain Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab